

Status: Currently Official on 15-Feb-2025
 Official Date: Official as of 01-May-2018
 Document Type: USP Monographs
 DocId: GUID-5C7C5E77-12F8-4ACC-821D-248E58CF128A_3_en-US
 DOI: https://doi.org/10.31003/USPNF_M43732_03_01
 DOI Ref: t80my

© 2025 USPC
 Do not distribute

Ivermectin Injection

» Ivermectin Injection is a sterile solution of Ivermectin in a suitable vehicle. It contains not less than 95.0 percent and not more than 105.0 percent of the labeled amount of ivermectin, calculated as the sum of component $\text{H}_2\text{B}_{1a}(\text{C}_{48}\text{H}_{74}\text{O}_{14})$ plus component $\text{H}_2\text{B}_{1b}(\text{C}_{47}\text{H}_{72}\text{O}_{14})$. The ratio of the contents, $\text{H}_2\text{B}_{1a}/(\text{H}_2\text{B}_{1a} + \text{H}_2\text{B}_{1b})$, is not less than 90.0 percent.

Packaging and storage—Preserve in single-dose or in multi-dose containers, preferably of Type I glass or plastic. Store at a temperature of not more than 30°.

Labeling—Label it to indicate that it is for veterinary use only.

USP REFERENCE STANDARDS (11)—

[USP Ivermectin RS](#)

Identification—

A: [THIN-LAYER CHROMATOGRAPHIC IDENTIFICATION TEST \(201\)](#)—

Test solution—Dissolve a volume of the Injection in methanol, dilute quantitatively, and stepwise if necessary, with methanol to obtain a solution containing 0.5 mg per mL of ivermectin, and filter.

Injection volume: 2 µL.

Developing solvent system: unsaturated chamber, consisting of a freshly prepared and equilibrated mixture of methylene chloride, methanol, and ammonium hydroxide (90:9:1).

Procedure—Remove the plate, allow to air dry, and examine under short- and long-wavelength UV light: the retardation factor, R_f , of the principal spot obtained from the *Test solution* corresponds to that obtained from the *Standard solution*.

B: The retention times of the two principal component peaks of ivermectin in the chromatogram of the *Assay preparation* corresponds to that of the two principal component peaks of ivermectin in the chromatogram of the *Standard preparation*, obtained as directed in the Assay.

BACTERIAL ENDOTOXINS TEST (85)—It contains not more than 0.016 USP Endotoxin Unit per µg of ivermectin.

STERILITY TESTS (71)—It meets the requirements when tested as directed for *Membrane Filtration* under *Test for Sterility of the Product to be Examined*.

Chromatographic purity—

Mobile phase and Chromatographic system—Proceed as directed in the Assay.

Standard solution—Dissolve an accurately weighed quantity of [USP Ivermectin RS](#) in methanol and dilute quantitatively, and stepwise if necessary, with methanol to obtain a 0.004 mg per mL solution.

Test solution—Dissolve a volume of the Injection in methanol and dilute quantitatively, and stepwise if necessary, with methanol to obtain a solution containing 0.4 mg of ivermectin per mL of solution, based on the label claim.

Procedure—Inject equal volumes (about 20 µL) of the *Test solution* and the *Standard solution* into the chromatograph, record the chromatograms, and measure all of the peak responses. Calculate the percentage of each impurity in the portion of Injection taken by the formula:

$$100(C_s/C_T)(r_i/r_s)$$

in which C_s is the concentration, in mg per mL, of ivermectin in the *Standard solution*; C_T is the concentration, in mg per mL, of ivermectin in the *Test solution*; r_i is the peak response for each individual peak obtained from the *Test solution*; and r_s is the ivermectin peak response obtained from the *Standard solution*. Not more than 2.7% of the peak with a relative retention time of about 1.3 to 1.5 to that of the principal peak is found; not more than 1.0% of any other impurity is found; and not more than 6.0% of total impurities is found. Disregard any peak below 0.05%.

Other requirements—It meets the requirements under [Injections and Implanted Drug Products \(1\)](#).

Assay—

Mobile phase—Prepare a filtered and degassed mixture of acetonitrile, methanol, and water (106:55:39). Make adjustments if necessary (see *System Suitability* under [Chromatography \(621\)](#)).

Standard preparation—Dissolve an accurately weighed quantity of [USP Ivermectin RS](#) in methanol and dilute quantitatively, and stepwise if necessary, with methanol to obtain a 0.4 mg per mL solution.

Assay preparation—Dilute a volume of Injection in methanol and dilute quantitatively, and stepwise if necessary, with methanol to obtain a solution containing 0.4 mg of ivermectin per mL of solution, based on the label claim.

Chromatographic system (see [CHROMATOGRAPHY \(621\)](#))—The liquid chromatograph is equipped with 245-nm detector and a 4.6-mm × 25-cm column that contains 5-μm packing L1. The flow rate is about 1.5 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the resolution, R , between the first peak (component H_2B_{1a}) and the second peak (component H_2B_{1b}) is not less than 3.0; and the relative standard deviation for replicate injections is not more than 2.0%, determined from the component H_2B_{1a} peak.

Procedure—Separately inject equal volumes (about 20 μL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the component H_2B_{1a} plus component H_2B_{1b} . Calculate the percentage of label claim of ivermectin ($H_2B_{1a} + H_2B_{1b}$) in the portion of Injection taken by the formula:

$$100(C_s/C_u)(r_u/r_s)$$

in which C_s is the concentration, in mg per mL, of [USP Ivermectin RS](#) in the *Standard preparation*; C_u is the concentration, in mg per mL, of ivermectin in the *Assay preparation*; r_u is the total peak response of H_2B_{1a} plus H_2B_{1b} peaks obtained from the *Assay preparation*; and r_s is the total peak response of H_2B_{1a} plus H_2B_{1b} peaks obtained from the *Standard preparation*. Calculate the ratio of the contents, in percent, of $H_2B_{1a}/(H_2B_{1a} + H_2B_{1b})$ in the portion of Injection taken by the formula:

$$100(r_1/r_u)$$

in which r_1 is the peak response of H_2B_{1a} obtained from the *Assay preparation*; and r_u is as defined above.

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
IVERMECTIN INJECTION	Documentary Standards Support	SM32020 Small Molecules 3
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	SM32020 Small Molecules 3

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 33(5)

Current DocID: GUID-5C7C5E77-12F8-4ACC-821D-248E58CF128A_3_en-US

Previous DocID: GUID-5C7C5E77-12F8-4ACC-821D-248E58CF128A_1_en-US

DOI: https://doi.org/10.31003/USPNF_M43732_03_01

DOI ref: [t80my](#)